Details for: API5
Gene ID: 8539
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: API5
Ensembl ID: ENSG00000166181
Description: apoptosis inhibitor 5
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 13.24rCSI 29.32%PRS 50.13
-
CSI 11.71rCSI 14.91%PRS 58.56
-
CSI 9.51rCSI 11.41%PRS 50.44
-
CSI 7.12rCSI 11.25%PRS 53.77
-
CSI 6.87rCSI 5.23%PRS 65.02
-
CSI 6.87rCSI 5.13%PRS 70.16
-
CSI 5.84rCSI 7.99%PRS 54.78
-
CSI 4.53rCSI 10.15%PRS 36.15
-
CSI 4.27rCSI 26.7%PRS 44.47
-
CSI 4.22rCSI 3.27%PRS 53.3
-
CSI 4.17rCSI 13.44%PRS 51.31
-
CSI 3.95rCSI 7.11%PRS 45.64
-
CSI 3.92rCSI 4.68%PRS 35.26
-
CSI 3.84rCSI 8.77%PRS 51.87
-
CSI 3.83rCSI 9.71%PRS 42.23
-
CSI 3.83rCSI 5.88%PRS 60.45
-
CSI 3.78rCSI 21.69%PRS 62.9
-
CSI 3.61rCSI 10.35%PRS 71.82
-
CSI 3.58rCSI 2.49%PRS 62.56
-
CSI 3.56rCSI 3.08%PRS 56.99
-
CSI 3.41rCSI 8.45%PRS 50.37
-
CSI 3.41rCSI 17.13%PRS 64.62
-
CSI 3.22rCSI 5.67%PRS 49.98
-
CSI 3.16rCSI 2.66%PRS 70.3
-
CSI 3.04rCSI 2.25%PRS 45.31
-
CSI 2.85rCSI 5.43%PRS 68.57
-
CSI 2.83rCSI 7.46%PRS 60.73
-
CSI 2.78rCSI 4.11%PRS 57.84
-
CSI 2.76rCSI 6.63%PRS 71.1
-
CSI 2.75rCSI 3.17%PRS 46.32
-
CSI 2.73rCSI 2.07%PRS 66.23
-
CSI 2.71rCSI 4.14%PRS 57.11
-
CSI 2.71rCSI 2.9%PRS 50.82
-
CSI 2.65rCSI 2.61%PRS 68.46
-
CSI 2.65rCSI 2.71%PRS 66.07
-
CSI 2.52rCSI 4.3%PRS 77.79
-
CSI 2.51rCSI 3.43%PRS 57.85
-
CSI 2.45rCSI 5.76%PRS 59.5
-
CSI 2.44rCSI 1.75%PRS 66.43
-
CSI 2.43rCSI 2.34%PRS 52.77
-
CSI 2.42rCSI 5.4%PRS 59.69
-
CSI 2.41rCSI 3.85%PRS 56.31
-
CSI 2.38rCSI 1.97%PRS 53.98
-
CSI 2.35rCSI 2.41%PRS 70.45
-
CSI 2.31rCSI 2.68%PRS 42.38
-
CSI 2.3rCSI 6.8%PRS 56.32
-
CSI 2.28rCSI 1.54%PRS 64.53
-
CSI 2.28rCSI 1.89%PRS 51.21
-
CSI 2.27rCSI 8.52%PRS 44.82
-
CSI 2.25rCSI 1.56%PRS 66.67
-
CSI 2.21rCSI 16.24%PRS 39.77
-
CSI 2.16rCSI 3.21%PRS 54.72
-
CSI 2.13rCSI 5.08%PRS 53.91
-
CSI 2.1rCSI 2.44%PRS 61.59
-
CSI 2.1rCSI 2.23%PRS 65.32
-
CSI 2.07rCSI 3.29%PRS 63.55
-
CSI 2.07rCSI 3.39%PRS 42.27
-
CSI 2.06rCSI 3.64%PRS 34.44
-
CSI 2.05rCSI 1.21%PRS 69.21
-
CSI 2.03rCSI 2.12%PRS 52.85
-
CSI 2.01rCSI 1.59%PRS 39.61
-
CSI 1.98rCSI 4.5%PRS 57.64
-
CSI 1.96rCSI 2.05%PRS 51.37
-
CSI 1.92rCSI 2.01%PRS 55.7
-
CSI 1.91rCSI 2.23%PRS 68.68
-
CSI 1.9rCSI 3.4%PRS 51.03
-
CSI 1.89rCSI 3.8%PRS 41.78
-
CSI 1.89rCSI 4.32%PRS 44.95
-
CSI 1.87rCSI 2.65%PRS 48.91
-
CSI 1.87rCSI 1.72%PRS 53.53
-
CSI 1.86rCSI 4.71%PRS 60.88
-
CSI 1.85rCSI 44.34%PRS 34.84
-
CSI 1.83rCSI 2.19%PRS 72.83
-
CSI 1.83rCSI 1.7%PRS 52.2
-
CSI 1.79rCSI 2.26%PRS 65.38
-
CSI 1.79rCSI 2.02%PRS 68.95
-
CSI 1.79rCSI 1.96%PRS 56.17
-
CSI 1.77rCSI 1.74%PRS 55.03
-
CSI 1.76rCSI 1.31%PRS 66.39
-
CSI 1.76rCSI 1.54%PRS 57.81
-
CSI 1.75rCSI 2.5%PRS 55.05
-
CSI 1.72rCSI 41.62%PRS 35.8
-
CSI 1.7rCSI 1.34%PRS 59.06
-
CSI 1.7rCSI 4.4%PRS 47.86
-
CSI 1.69rCSI 1.99%PRS 55.56
-
CSI 1.69rCSI 6.58%PRS 73.04
-
CSI 1.69rCSI 1.48%PRS 40.93
-
CSI 1.65rCSI 1.59%PRS 43.02
-
CSI 1.62rCSI 1.13%PRS 54.9
-
CSI 1.61rCSI 1.2%PRS 67.82
-
CSI 1.61rCSI 3.55%PRS 39.64
-
CSI 1.6rCSI 3.33%PRS 49.83
-
CSI 1.6rCSI 2.77%PRS 42.7
-
CSI 1.59rCSI 2.13%PRS 61.13
-
CSI 1.46rCSI 1.89%PRS 36.47
-
CSI 1.46rCSI 1.87%PRS 50.19
-
CSI 1.43rCSI 4.48%PRS 36.8
-
CSI 1.43rCSI 2.55%PRS 67.23
-
CSI 1.43rCSI 4.57%PRS 49.29
-
CSI 1.43rCSI 3.72%PRS 51.67
-
CSI 0.1rCSI 0.9%PRS 67.1%
-
CSI 0.2rCSI 4.7%PRS 74.4%
-
CSI 0.2rCSI 1.0%PRS 63.3%
-
CSI 0.3rCSI 1.7%PRS 36.8%
-
CSI 0.4rCSI 0.9%PRS 54.9%
-
CSI 0.5rCSI 1.2%PRS 44.3%
-
CSI 0.5rCSI 1.2%PRS 65.4%
-
CSI 0.5rCSI 2.0%PRS 69.6%
-
CSI 0.5rCSI 1.9%PRS 67.2%
-
CSI 0.5rCSI 1.4%PRS 66.0%
-
CSI 0.5rCSI 2.7%PRS 66.5%
-
CSI 0.5rCSI 2.1%PRS 71.5%
-
CSI 0.5rCSI 1.3%PRS 47.6%
-
CSI 0.5rCSI 1.3%PRS 40.7%
-
CSI 0.6rCSI 1.0%PRS 35.4%
-
CSI 0.6rCSI 2.3%PRS 34.1%
-
CSI 0.6rCSI 2.8%PRS 44.5%
-
CSI 0.7rCSI 2.1%PRS 39.2%
-
CSI 0.7rCSI 1.1%PRS 50.4%
-
CSI 0.7rCSI 1.7%PRS 63.1%
-
CSI 0.7rCSI 1.2%PRS 62.0%
-
CSI 0.7rCSI 2.7%PRS 36.2%
-
CSI 0.8rCSI 1.1%PRS 48.9%
-
CSI 0.8rCSI 2.2%PRS 42.9%
-
CSI 0.8rCSI 1.3%PRS 42.6%
-
CSI 0.8rCSI 3.5%PRS 51.5%
-
CSI 0.8rCSI 0.7%PRS 49.2%
-
CSI 0.8rCSI 1.2%PRS 42.8%
-
CSI 0.8rCSI 2.8%PRS 40.4%
-
CSI 0.9rCSI 1.3%PRS 56.0%
-
CSI 0.9rCSI 1.4%PRS 46.9%
-
CSI 1.0rCSI 1.4%PRS 55.5%
-
CSI 1.0rCSI 1.2%PRS 60.8%
-
CSI 1.0rCSI 1.3%PRS 45.1%
-
CSI 1.0rCSI 0.8%PRS 57.2%
-
CSI 1.0rCSI 1.5%PRS 67.8%
-
CSI 1.0rCSI 2.4%PRS 34.2%
-
CSI 1.0rCSI 0.9%PRS 63.0%
-
CSI 1.0rCSI 1.3%PRS 54.6%
-
CSI 1.0rCSI 1.7%PRS 37.5%
-
CSI 1.1rCSI 1.4%PRS 58.0%
-
CSI 1.1rCSI 2.4%PRS 61.5%
-
CSI 1.1rCSI 3.1%PRS 48.5%
-
CSI 1.1rCSI 2.6%PRS 42.7%
-
CSI 1.2rCSI 1.5%PRS 53.5%
-
CSI 1.2rCSI 1.7%PRS 64.0%
-
CSI 1.2rCSI 4.9%PRS 50.8%
-
CSI 1.2rCSI 1.3%PRS 49.3%
-
CSI 1.2rCSI 2.0%PRS 45.7%
-
CSI 1.2rCSI 1.0%PRS 51.9%
-
CSI 1.2rCSI 4.8%PRS 59.7%
-
CSI 1.3rCSI 2.2%PRS 44.6%
-
CSI 1.3rCSI 1.6%PRS 62.7%
-
CSI 1.3rCSI 1.6%PRS 33.7%
-
CSI 1.3rCSI 1.2%PRS 50.9%
-
CSI 1.3rCSI 1.0%PRS 56.9%
-
CSI 1.3rCSI 1.3%PRS 52.7%
-
CSI 1.4rCSI 5.5%PRS 48.5%
-
CSI 1.4rCSI 1.7%PRS 48.4%
-
CSI 1.4rCSI 1.8%PRS 66.1%
-
CSI 1.4rCSI 2.0%PRS 62.3%
-
CSI 1.4rCSI 2.6%PRS 41.4%
-
CSI 1.4rCSI 1.3%PRS 60.8%
-
CSI 1.4rCSI 2.1%PRS 53.0%
-
CSI 1.4rCSI 1.1%PRS 53.6%
-
CSI 1.4rCSI 2.2%PRS 45.0%
-
CSI 1.4rCSI 1.4%PRS 46.1%
-
CSI 1.4rCSI 2.0%PRS 51.7%
-
CSI 1.4rCSI 3.7%PRS 51.7%
-
CSI 1.4rCSI 4.6%PRS 49.3%
-
CSI 1.4rCSI 2.6%PRS 67.2%
-
CSI 1.4rCSI 4.5%PRS 36.8%
-
CSI 1.5rCSI 1.9%PRS 50.2%
-
CSI 1.5rCSI 1.9%PRS 36.5%
-
CSI 1.6rCSI 2.1%PRS 61.1%
-
CSI 1.6rCSI 2.8%PRS 42.7%
-
CSI 1.6rCSI 3.3%PRS 49.8%
-
CSI 1.6rCSI 3.6%PRS 39.6%
-
CSI 1.6rCSI 1.2%PRS 67.8%
-
CSI 1.6rCSI 1.1%PRS 54.9%
-
CSI 1.7rCSI 1.6%PRS 43.0%
-
CSI 1.7rCSI 1.5%PRS 40.9%
-
CSI 1.7rCSI 6.6%PRS 73.0%
-
CSI 1.7rCSI 2.0%PRS 55.6%
-
CSI 1.7rCSI 4.4%PRS 47.9%
-
CSI 1.7rCSI 1.3%PRS 59.1%
-
CSI 1.7rCSI 41.6%PRS 35.8%
-
CSI 1.8rCSI 2.5%PRS 55.1%
-
CSI 1.8rCSI 1.5%PRS 57.8%
-
CSI 1.8rCSI 1.3%PRS 66.4%
-
CSI 1.8rCSI 1.7%PRS 55.0%
-
CSI 1.8rCSI 2.0%PRS 56.2%
-
CSI 1.8rCSI 2.0%PRS 69.0%
-
CSI 1.8rCSI 2.3%PRS 65.4%
-
CSI 1.8rCSI 1.7%PRS 52.2%
-
CSI 1.8rCSI 2.2%PRS 72.8%
-
CSI 1.9rCSI 44.3%PRS 34.8%
-
CSI 1.9rCSI 4.7%PRS 60.9%
-
CSI 1.9rCSI 1.7%PRS 53.5%
-
CSI 1.9rCSI 2.7%PRS 48.9%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 2078202284
Symbol: API5_HUMAN
Name: Antiapoptosis clone 11 protein
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 9307294
Title: AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal.
PubMed ID: 9307294
PubMed ID: 10393420
Title: Molecular cloning and fine mapping of API5L1, a novel human gene strongly related to an antiapoptotic gene.
PubMed ID: 10393420
DOI: 10.1159/000015247
PubMed ID: 11075807
Title: FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear putatively antiapoptotic factor, interacts specifically with FGF-2.
PubMed ID: 11075807
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 16554811
Title: Human chromosome 11 DNA sequence and analysis including novel gene identification.
PubMed ID: 16554811
DOI: 10.1038/nature04632
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 8889549
Title: Generation and analysis of 280,000 human expressed sequence tags.
PubMed ID: 8889549
DOI: 10.1101/gr.6.9.807
PubMed ID: 10780674
Title: AAC-11 overexpression induces invasion and protects cervical cancer cells from apoptosis.
PubMed ID: 10780674
PubMed ID: 11557113
Title: Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in non-small cell lung cancer.
PubMed ID: 11557113
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 17112319
Title: Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo.
PubMed ID: 17112319
PubMed ID: 17827341
Title: The antiapoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B cell chronic lymphoid leukemia.
PubMed ID: 17827341
DOI: 10.1189/jlb.0607425
PubMed ID: 19387494
Title: The antiapoptotic protein AAC-11 interacts with and regulates Acinus-mediated DNA fragmentation.
PubMed ID: 19387494
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 21406692
Title: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
PubMed ID: 21406692
PubMed ID: 22814378
Title: N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.
PubMed ID: 22814378
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 24129315
Title: Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.
PubMed ID: 24129315
PubMed ID: 22334682
Title: Helical repeat structure of apoptosis inhibitor 5 reveals protein-protein interaction modules.
PubMed ID: 22334682
Sequence Information:
- Length: 524
- Mass: 59005
- Checksum: A2EA6BE4D8318BB9
- Sequence:
MPTVEELYRN YGILADATEQ VGQHKDAYQV ILDGVKGGTK EKRLAAQFIP KFFKHFPELA DSAINAQLDL CEDEDVSIRR QAIKELPQFA TGENLPRVAD ILTQLLQTDD SAEFNLVNNA LLSIFKMDAK GTLGGLFSQI LQGEDIVRER AIKFLSTKLK TLPDEVLTKE VEELILTESK KVLEDVTGEE FVLFMKILSG LKSLQTVSGR QQLVELVAEQ ADLEQTFNPS DPDCVDRLLQ CTRQAVPLFS KNVHSTRFVT YFCEQVLPNL GTLTTPVEGL DIQLEVLKLL AEMSSFCGDM EKLETNLRKL FDKLLEYMPL PPEEAENGEN AGNEEPKLQF SYVECLLYSF HQLGRKLPDF LTAKLNAEKL KDFKIRLQYF ARGLQVYIRQ LRLALQGKTG EALKTEENKI KVVALKITNN INVLIKDLFH IPPSYKSTVT LSWKPVQKVE IGQKRASEDT TSGSPPKKSS AGPKRDARQI YNPPSGKYSS NLGNFNYEQR GAFRGSRGGR GWGTRGNRSR GRLY
Genular Protein ID: 2661738722
Symbol: B4DDR3_HUMAN
Name: N/A
UniProtKB Accession Codes:
Database IDs:
Sequence Information:
- Length: 331
- Mass: 37508
- Checksum: D6E3EC7C3DDAFCB9
- Sequence:
MPTVEELYRN YGILADATEQ VGQHKDAYQV ILDGVKGGTK EKRLAAQFIP KFFKHFPELA DSAINAQLDL CEDEDVSIRR QAIKELPQFA TGENLPRVAD ILTQLLQTDD SAEFNLVNNA LLSIFKMEKL ETNLRKLFDK LLEYMPLPPE EAENGENAGN EEPKLQFSYV ECLLYSFHQL GRKLPDFLTA KLNAEKLKDF KIRLQYFARG LQVYIRQLRL ALQGKTGEAL KTEENKIKVV ALKITNNINV LIKDLFHIPP SYKSTVTLSW KPVQKVEIGQ KRASEDTTSG SPPKKSSAGP KRDARQIYNP PSGKYSSNLG NFNYERSLQG K